Search

Displaying results 1581 - 1590 of 4262 in total
  1. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    Casimersen is currently marketed under the tradename AMONDYS 45™ by Sarepta Therapeutics, Inc.[L32118] … However, the specific mutations, and hence the precise exon skipping, targeted by each is different.

  2. Drug

    Brimonidine

    go.drugbank.com/drugs/DB00484
    ApprovedInvestigational

    [A178948,A178969] Ophthalmically, brimonidine is used to lower intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. … [A178948] The topical form of brimonidine was approved by the FDA in August 2013 for the symptomatic treatment of persistent facial erythema of rosacea in adults.

  3. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    [A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … [A231159] Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction

  4. Drug

    Framycetin

    go.drugbank.com/drugs/DB00452
    ApprovedInvestigational

    A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)

  5. Drug

    Pentetrazol

    go.drugbank.com/drugs/DB13415
    ApprovedWithdrawn

    Pentetrazol, also known as pentylenetetrazole, is a gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptor antagonist that was approved by the FDA until 1982.[A254437]

  6. Drug

    Palonosetron

    go.drugbank.com/drugs/DB00377
    ApprovedInvestigational

    HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by

  7. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.

  8. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  9. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    It works by relaxing muscles in the airways to improve breathing.

  10. Drug

    Pseudoephedrine

    go.drugbank.com/drugs/DB00852
    Approved

    Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.